ANDA Litigation Settlements

Summer 2018

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms
AstraZeneca AB v. Mylan Pharms. Inc., 17-1778 (Fed. Cir.) Onglyza® (saxagliptin HCl tablets)
Kombiglyze XR™ (saxagliptin HCl / metformin HCl extended-release tablets)
RE44,186 The Federal Circuit granted a joint motion by the parties to voluntarily drop the appeal with each side bearing its own fees and costs.
The district court concluded that patent-in-suit claims were non-obviousness.

Oren D. Langer


Managing Partner, New York Office
Member of Executive Board

Back to Top